RESUMO
Importance: A 2019 review for the US Preventive Services Task Force (USPSTF) found oral preexposure prophylaxis (PrEP) associated with decreased HIV infection risk vs placebo or no PrEP in adults at increased HIV acquisition risk. Newer PrEP regimens are available. Objective: To update the 2019 review on PrEP, to inform the USPSTF. Data Sources: Ovid MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Embase (January 2018 to May 16, 2022); surveillance through March 24, 2023. Study Selection: Randomized clinical trials of PrEP vs placebo or no PrEP or newer vs older PrEP regimens and diagnostic accuracy studies of instruments for predicting incident HIV infection. Data Extraction and Synthesis: Dual review of titles and abstracts, full-text articles, study quality, and data abstraction. Data were pooled using the DerSimonian and Laird random-effects model. Main Outcomes and Measures: HIV acquisition, mortality, and harms; and diagnostic test accuracy. Results: Thirty-two studies were included in the review (20 randomized clinical trials [N = 36â¯543] and 12 studies of diagnostic accuracy [N = 5â¯544â¯500]). Eleven trials in the 2019 review found oral PrEP associated with decreased HIV infection risk vs placebo or no PrEP (n = 18â¯172; relative risk [RR], 0.46 [95% CI, 0.33-0.66]). Higher adherence was associated with greater efficacy. One new trial (n = 5335) found oral tenofovir alafenamide/emtricitabine (TAF/FTC) to be noninferior to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in men who have sex with men (RR, 0.47 [95% CI, 0.19-1.14]). Two new trials found long-acting injectable cabotegravir associated with decreased risk of HIV infection vs oral TDF/FTC (RR, 0.33 [95% CI, 0.18-0.62] in cisgender men who have sex with men and transgender women [n = 4490] and RR, 0.11 [95% CI, 0.04-0.31] in cisgender women [n = 3178]). Discrimination of instruments for predicting incident HIV infection was moderate in men who have sex with men (5 studies; n = 25â¯488) and moderate to high in general populations of persons without HIV (2 studies; n = 5â¯477â¯291). Conclusions and Relevance: In adults at increased HIV acquisition risk, oral PrEP was associated with decreased risk of acquiring HIV infection compared with placebo or no PrEP. Oral TAF/FTC was noninferior to oral TDF/FTC, and injectable cabotegravir reduced the risk of HIV infection compared with oral TDF/FTC in the populations studied.
Assuntos
Fármacos Anti-HIV , Infecções por HIV , Profilaxia Pré-Exposição , Minorias Sexuais e de Gênero , Adulto , Feminino , Humanos , Masculino , Administração Oral , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/uso terapêutico , Emtricitabina/uso terapêutico , Infecções por HIV/prevenção & controle , Homossexualidade Masculina , Injeções , Guias de Prática Clínica como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto , Risco , Tenofovir/uso terapêuticoRESUMO
BACKGROUND: Data suggest that the effects of coronavirus disease 2019 (COVID-19) differ among U.S. racial/ethnic groups. PURPOSE: To evaluate racial/ethnic disparities in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates and COVID-19 outcomes, factors contributing to disparities, and interventions to reduce them. DATA SOURCES: English-language articles in MEDLINE, PsycINFO, CINAHL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus, searched from inception through 31 August 2020. Gray literature sources were searched through 2 November 2020. STUDY SELECTION: Observational studies examining SARS-CoV-2 infections, hospitalizations, or deaths by race/ethnicity in U.S. settings. DATA EXTRACTION: Single-reviewer abstraction confirmed by a second reviewer; independent dual-reviewer assessment of quality and strength of evidence. DATA SYNTHESIS: 37 mostly fair-quality cohort and cross-sectional studies, 15 mostly good-quality ecological studies, and data from the Centers for Disease Control and Prevention and APM Research Lab were included. African American/Black and Hispanic populations experience disproportionately higher rates of SARS-CoV-2 infection, hospitalization, and COVID-19-related mortality compared with non-Hispanic White populations, but not higher case-fatality rates (mostly reported as in-hospital mortality) (moderate- to high-strength evidence). Asian populations experience similar outcomes to non-Hispanic White populations (low-strength evidence). Outcomes for other racial/ethnic groups have been insufficiently studied. Health care access and exposure factors may underlie the observed disparities more than susceptibility due to comorbid conditions (low-strength evidence). LIMITATIONS: Selection bias, missing race/ethnicity data, and incomplete outcome assessments in cohort and cross-sectional studies must be considered. In addition, adjustment for key demographic covariates was lacking in ecological studies. CONCLUSION: African American/Black and Hispanic populations experience disproportionately higher rates of SARS-CoV-2 infection and COVID-19-related mortality but similar rates of case fatality. Differences in health care access and exposure risk may be driving higher infection and mortality rates. PRIMARY FUNDING SOURCE: Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development. (PROSPERO: CRD42020187078).
Assuntos
COVID-19/etnologia , COVID-19/mortalidade , Acessibilidade aos Serviços de Saúde , Disparidades nos Níveis de Saúde , Hospitalização/estatística & dados numéricos , Negro ou Afro-Americano/estatística & dados numéricos , Asiático/estatística & dados numéricos , COVID-19/terapia , Hispânico ou Latino/estatística & dados numéricos , Humanos , Pandemias , Fatores de Risco , SARS-CoV-2 , População Branca/estatística & dados numéricosAssuntos
Betacoronavirus , Infecções por Coronavirus/diagnóstico , Febre/diagnóstico , Neutropenia/diagnóstico , Pneumonia Viral/diagnóstico , COVID-19 , Infecções por Coronavirus/sangue , Infecções por Coronavirus/complicações , Diagnóstico Diferencial , Febre/sangue , Febre/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Neutropenia/sangue , Neutropenia/etiologia , Pandemias , Pneumonia Viral/sangue , Pneumonia Viral/complicações , SARS-CoV-2RESUMO
BACKGROUND: Pre-Exposure Prophylaxis (PrEP) to prevent transmission of human immunodeficiency virus (HIV) among people who inject drugs (PWID) has demonstrated efficacy yet awareness of PrEP among PWID is low. METHODS: 2018 National Behavioral Health Survey data from the Portland, Oregon metropolitan statistical area was analyzed with chi-squared tests and generalized linear models to determine correlates of PrEP awareness among PWID. RESULTS: 80% of the sample had at least one indication for PrEP and 15% of the sample was aware of PrEP. Factors associated with higher PrEP awareness were: higher education level (PR = 1.083, CI = 1.018-1.153, p = .012), reporting transactional sex (PR = 1.154, CI = 1.019-1.307, p = .024), and men who have sex with men reporting condomless sex (PR = 1.376, CI = 1.081-1.752, p = .010). Lack of a usual source of care (PR = 0.884, CI = 0.824-0.949, p < .001) was negatively associated with PrEP awareness. CONCLUSIONS: Interventions to increase PrEP awareness need to target groups with particularly low awareness and be delivered in settings accessible to PWID.
Assuntos
Fármacos Anti-HIV , Usuários de Drogas , Infecções por HIV , Profilaxia Pré-Exposição , Minorias Sexuais e de Gênero , Abuso de Substâncias por Via Intravenosa , Masculino , Humanos , Abuso de Substâncias por Via Intravenosa/complicações , Abuso de Substâncias por Via Intravenosa/epidemiologia , Homossexualidade Masculina , HIV , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Infecções por HIV/complicações , Oregon/epidemiologia , Fármacos Anti-HIV/uso terapêuticoRESUMO
The present study was designed to investigate the mechanism associated with dual-task interference in a psychological refractory period (PRP) paradigm. We used a simple reaction time paradigm consisting of a vocal response (R1) and key-lift task (R2) with a stimulus onset asynchrony (SOA) between 100ms and 1500ms. On selected trials we implemented a startling acoustic stimulus concurrent with the second stimulus to determine if we could involuntarily trigger the second response. Our results indicated that the PRP delay in the second response was present for both control and startle trials at short SOAs, suggesting the second response was not prepared in advance. These results support a response preparation bottleneck and can be explained via a neural activation model of preparation. In addition, we found that the reflexive startle activation was reduced in the dual-task condition for all SOAs, a result we attribute to prepulse inhibition associated with dual-task processing.